Cargando…
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
OBJECTIVES: To evaluate the efficacy and safety of regdanvimab, a neutralizing antibody, in patients with mild-to-moderate SARS-CoV-2 including against the Delta variant. METHODS: A single-center, retrospective, observational cohort study in adults with confirmed COVID-19. The primary end point was...
Autores principales: | Jang, Young Rock, Oh, Yoon Ju, Kim, Jin Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822548/ https://www.ncbi.nlm.nih.gov/pubmed/36623794 http://dx.doi.org/10.1016/j.ijid.2022.12.035 |
Ejemplares similares
-
Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022) -
Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023) -
Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
por: Lee, Chan Mi, et al.
Publicado: (2022) -
Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022) -
Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)